Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Plozasiran sodium by Arrowhead Pharmaceuticals for Familial Chylomicronemia (Type I Hyperlipoproteinemia): Likelihood of Approval
Plozasiran sodium is under clinical development by Arrowhead Pharmaceuticals and currently in Pre-Registration for Familial Chylomicronemia (Type I Hyperlipoproteinemia). According...
Plozasiran sodium by Arrowhead Pharmaceuticals for Hypertriglyceridemia: Likelihood of Approval
Plozasiran sodium is under clinical development by Arrowhead Pharmaceuticals and currently in Phase III for Hypertriglyceridemia. According to GlobalData, Phase...
AROC-3 by Arrowhead Pharmaceuticals for IgA Nephropathy (Berger's Disease): Likelihood of Approval
AROC-3 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for IgA Nephropathy (Berger's Disease). According to...
AROMMP-7 by Arrowhead Pharmaceuticals for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
AROMMP-7 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for Idiopathic Pulmonary Fibrosis. According to GlobalData,...
Zodasiran by Arrowhead Pharmaceuticals for Mixed Dyslipidemia: Likelihood of Approval
Zodasiran is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for Mixed Dyslipidemia. According to GlobalData, Phase...
Zodasiran by Arrowhead Pharmaceuticals for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia): Likelihood of Approval
Zodasiran is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). According...
AROC-3 by Arrowhead Pharmaceuticals for IgA Nephropathy (Berger's Disease): Likelihood of Approval
AROC-3 is under clinical development by Arrowhead Pharmaceuticals and currently in Phase II for IgA Nephropathy (Berger's Disease). According to...
Risk adjusted net present value: What is the current valuation of Arrowhead Pharmaceuticals's Zodasiran?
Zodasiran is an antisense rnai oligonucleotide commercialized by Arrowhead Pharmaceuticals, with a leading Phase II program in Homozygous Familial Hypercholesterolemia...